Search: onr:"swepub:oai:DiVA.org:liu-184375" > Long-term outcomes ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 07661naa a2200925 4500 | |
001 | oai:DiVA.org:liu-184375 | |
003 | SwePub | |
008 | 220421s2022 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:149187043 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1843752 URI |
024 | 7 | a https://doi.org/10.1007/s00134-022-06677-22 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1491870432 URI |
040 | a (SwePub)liud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Granholm, Andersu Rigshosp, Denmark; Collaborat Res Intens Care CRIC, Denmark4 aut |
245 | 1 0 | a Long-term outcomes of dexamethasone 12 mg versus 6 mg in patients with COVID-19 and severe hypoxaemia |
264 | c 2022-03-31 | |
264 | 1 | b SPRINGER,c 2022 |
338 | a print2 rdacarrier | |
500 | a Funding Agencies|Novo Nordisk FoundationNovo Nordisk FoundationNovocure Limited; Research Council of Rigshospitalet [0062998, E-22703-06] | |
520 | a Purpose We assessed long-term outcomes of dexamethasone 12 mg versus 6 mg given daily for up to 10 days in patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia. Methods We assessed 180-day mortality and health-related quality of life (HRQoL) using EuroQoL (EQ)-5D-5L index values and EQ visual analogue scale (VAS) in the international, stratified, blinded COVID STEROID 2 trial, which randomised 1000 adults with confirmed COVID-19 receiving at least 10 L/min of oxygen or mechanical ventilation in 26 hospitals in Europe and India. In the HRQoL analyses, higher values indicated better outcomes, and deceased patients were given a score of zero. Results We obtained vital status at 180 days for 963 of 982 patients (98.1%) in the intention-to-treat population, EQ-5D-5L index value data for 922 (93.9%) and EQ VAS data for 924 (94.1%). At 180 days, 164 of 486 patients (33.7%) had died in the 12 mg group versus 184 of 477 (38.6%) in the 6 mg group [adjusted risk difference - 4.3%; 99% confidence interval (CI) - 11.7-3.0; relative risk 0.89; 0.72-1.09; P = 0.13]. The adjusted mean differences between the 12 mg and the 6 mg groups in EQ-5D-5L index values were 0.06 (99% CI - 0.01 to 0.12; P = 0.10) and in EQ VAS scores 4 (- 3 to 10; P = 0.22). Conclusion Among patients with COVID-19 and severe hypoxaemia, dexamethasone 12 mg compared with 6 mg did not result in statistically significant improvements in mortality or HRQoL at 180 days, but the results were most compatible with benefit from the higher dose. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Gastroenterologi0 (SwePub)302132 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Gastroenterology and Hepatology0 (SwePub)302132 hsv//eng |
653 | a COVID-19; Hypoxaemia; Critical illness; Corticosteroids; Quality of life; Mortality | |
700 | 1 | a Kjaer, Maj-Brit Norregaardu Rigshosp, Denmark; Collaborat Res Intens Care CRIC, Denmark4 aut |
700 | 1 | a Munch, Marie Warreru Rigshosp, Denmark; Collaborat Res Intens Care CRIC, Denmark4 aut |
700 | 1 | a Myatra, Sheila Nainanu Tata Mem Hosp, India4 aut |
700 | 1 | a Vijayaraghavan, Bharath Kumar Tirupakuzhiu Apollo Hosp, India; Chennai Crit Care Consultants, India; George Inst Global Hlth, India4 aut |
700 | 1 | a Cronhjort, Mariau Karolinska Institutet,Karolinska Inst, Sweden4 aut |
700 | 1 | a Wahlin, Rebecka Rubensonu Karolinska Institutet,Karolinska Inst, Sweden4 aut |
700 | 1 | a Jakob, Stephan M.u Univ Bern, Switzerland4 aut |
700 | 1 | a Cioccari, Lucau Univ Bern, Switzerland4 aut |
700 | 1 | a Vesterlund, Gitte Kingou Rigshosp, Denmark; Collaborat Res Intens Care CRIC, Denmark4 aut |
700 | 1 | a Meyhoff, Tine Sylvestu Rigshosp, Denmark; Collaborat Res Intens Care CRIC, Denmark4 aut |
700 | 1 | a Helleberg, Marieu Copenhagen Univ Hosp, Denmark4 aut |
700 | 1 | a Moller, Morten Hylanderu Rigshosp, Denmark; Collaborat Res Intens Care CRIC, Denmark4 aut |
700 | 1 | a Benfield, Thomasu Copenhagen Univ Hosp Amager & Hvidovre, Denmark4 aut |
700 | 1 | a Venkatesh, Balasubramanianu Univ New South Wales, Australia4 aut |
700 | 1 | a Hammond, Naomi E.u Univ New South Wales, Australia; Royal North Shore Hosp, Australia4 aut |
700 | 1 | a Chew, Michelle S,d 1969-u Linköpings universitet,Avdelningen för klinisk kemi och farmakologi,Medicinska fakulteten,Region Östergötland, ANOPIVA US4 aut0 (Swepub:liu)micch61 |
700 | 1 | a Bassi, Abhinavu Chennai Crit Care Consultants, India4 aut |
700 | 1 | a John, Oommenu Chennai Crit Care Consultants, India; Manipal Acad Higher Educ, India4 aut |
700 | 1 | a Jha, Vivekanandu Chennai Crit Care Consultants, India; Manipal Acad Higher Educ, India; Imperial Coll London, England4 aut |
700 | 1 | a Kristiansen, Klaus Tjelleu Univ Copenhagen, Denmark4 aut |
700 | 1 | a Ulrik, Charlotte Suppliu Univ Copenhagen, Denmark4 aut |
700 | 1 | a Jorgensen, Vibeke Lindu Copenhagen Univ Hosp, Denmark4 aut |
700 | 1 | a Smitt, Margitu Copenhagen Univ Hosp, Denmark4 aut |
700 | 1 | a Bestle, Morten H.u Copenhagen Univ Hosp North Zealand, Denmark; Univ Copenhagen, Denmark4 aut |
700 | 1 | a Andreasen, Anne Sofieu Copenhagen Univ Hosp Herlev, Denmark4 aut |
700 | 1 | a Poulsen, Lone Musaeusu Zealand Univ Hosp, Denmark4 aut |
700 | 1 | a Rasmussen, Bodil Steenu Collaborat Res Intens Care CRIC, Denmark; Aalborg Univ Hosp, Denmark4 aut |
700 | 1 | a Brochner, Anne Craveirou Collaborat Res Intens Care CRIC, Denmark; Univ Hosp Southern Denmark, Denmark4 aut |
700 | 1 | a Strom, Thomasu Odense Univ Hosp, Denmark; Univ Hosp Southern, Denmark4 aut |
700 | 1 | a Moller, Andersu Naestved Slagelse Ringsted Hosp, Denmark4 aut |
700 | 1 | a Khan, Mohd Saifu Rajendra Inst Med Sci, India4 aut |
700 | 1 | a Padmanaban, Ajayu Apollo Hosp, India4 aut |
700 | 1 | a Divatia, Jigeeshu Vasishthau Tata Mem Hosp, India4 aut |
700 | 1 | a Saseedharan, Sanjithu SL Raheja Hosp, India,Sir HN Reliance Fdn Hosp & Res Ctr, India,Herning Hosp, Denmark4 aut |
700 | 1 | a Borawake, Kapilu Vishwaraj Hosp, India4 aut |
700 | 1 | a Kapadia, Farhadu Hinduja Hosp, India4 aut |
700 | 1 | a Dixit, Subhalu Sanjeevan Hosp, India4 aut |
700 | 1 | a Chawla, Rajeshu Indraprastha Apollo Hosp, India4 aut |
700 | 1 | a Shukla, Urviu Symbiosis Univ Hosp & Res Ctr, India4 aut |
700 | 1 | a Amin, Pravinu Bombay Hosp Inst Med Sci, India4 aut |
700 | 1 | a Chew, Michelle S,d 1969-u Linköpings universitet,Avdelningen för klinisk kemi och farmakologi,Medicinska fakulteten,Region Östergötland, ANOPIVA US4 aut0 (Swepub:liu)micch61 |
700 | 1 | a Wamberg, Christian Aageu Bispebjerg Hosp, Denmark4 aut |
700 | 1 | a Bose, Neetau Gotri Gen Hosp, India4 aut |
700 | 1 | a Shah, Mehul S.u Sir HN Reliance Fdn Hosp & Res Ctr, India4 aut |
700 | 1 | a Darfelt, Iben S.u Herning Hosp, Denmark4 aut |
700 | 1 | a Gluud, Christianu Copenhagen Univ Hosp, Denmark; Univ Southern Denmark, Denmark4 aut |
700 | 1 | a Lange, Theisu Univ Copenhagen, Denmark4 aut |
700 | 1 | a Perner, Andersu Rigshosp, Denmark; Collaborat Res Intens Care CRIC, Denmark; Univ New South Wales, Australia4 aut |
710 | 2 | a Rigshosp, Denmark; Collaborat Res Intens Care CRIC, Denmarkb Tata Mem Hosp, India4 org |
773 | 0 | t Intensive Care Medicined : SPRINGERg 48, s. 580-589q 48<580-589x 0342-4642x 1432-1238 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-184375 |
856 | 4 8 | u https://doi.org/10.1007/s00134-022-06677-2 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:149187043 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.